Annals of Laboratory Medicine

Korean Society for Laboratory Medicine (대한진단검사의학회)
권호 표지
DOI QR코드

DOI QR Code

Response to the Comments on 'Point of Care D-Dimer Testing in the Emergency Department-A Bioequivalence Study' and Erratum to the Results

  • Perveen, Shuhana (Emergency Department, Westmead Hospital) ;
  • Unwin, Danielle (Emergency Department, Westmead Hospital) ;
  • Shetty, Amith L. (Emergency Department, Westmead Hospital) ;
  • Byth, Karen (Millennium Research Institute)
  • Received : 2013.04.30
  • Accepted : 2013.08.20
  • Published : 2014.01.02
⟨ Previous Next ⟩

Abstract

Keywords

References

  1. Perveen S, Unwin D, Shetty AL. Point of care D-dimer testing in the emergency department: a bioequivalence study. Ann Lab Med 2013;33:34-8. https://doi.org/10.3343/alm.2013.33.1.34
  2. Vossen JA, Albrektson J, Sensarma A, Williams SC. Clinical usefulness of adjusted D-dimer cut-off values to exclude pulmonary embolism in a community hospital emergency department patient population. Acta Radiol 2012;53:765-8. https://doi.org/10.1258/ar.2012.120105
  3. Leng O and Sitaraaman HB. Application of age-adjusted D-dimer threshold for exclusion thromboembolism (PTE) in older patients: a retrospective study. Acute Med 2012;11:129-32.
  4. Douma RA, le Gal G, Sohne M, Righini M, Kamphuisen PW, Perrier A, et al. Potential of an age adjusted D-dimer cut-off value to improve the exclusion of pulmonary embolism in older patients: a retrospective analysis of three large cohorts. BMJ 2010;340:c1475. https://doi.org/10.1136/bmj.c1475
  5. Douma RA, van Sluis GL, Kamphuisen PW, Sohne M, Leebeek FW, Bossuyt PM, et al. Clinical decision rule and D-dimer have lower clinical utility to exclude pulmonary embolism in cancer patients. Explanations and potential ameliorations. Thromb Haemost 2010;104:831-6. https://doi.org/10.1160/TH10-02-0093
  6. Mochizuki S, Yoshino T, Kojima T, Fuse N, Ikematsu H, Minashi K, et al. Therapeutic significance of a D-dimer cut-off level of >3 ${\mu}g/ml $in colorectal cancer patients treated with standard chemotherapy plus bevacizumab. Jpn J Clin Oncol 2010;40:933-7. https://doi.org/10.1093/jjco/hyq058
  7. Duriseti RS and Brandeau ML. Cost-effectiveness of strategies for diagnosing pulmonary embolism among emergency department patients presenting with undifferentiated symptoms. Ann Emerg Med 2010;56:321-32. e10. https://doi.org/10.1016/j.annemergmed.2010.03.029
  8. Sukhu K, Beavis J, Baker PM, Keeling DM. Comparison of an immuno-turbidometric method (STalia D-DI) with an established enzyme linked fluorescent assay (VIDAS) D-dimer for the exclusion of venous thromboembolism. Int J Lab Hematol 2008;30:200-4. https://doi.org/10.1111/j.1751-553X.2007.00942.x
  9. European Medicines Agency. Guideline on the investigation of bioequivalence. In: European Medicines Agency, ed. CPMP/EWP/QWP/1401/98 Rev. 1. London: European Medicines Agency, 2010:1-27.
  10. U.S. Department of Health and Human Services FaDA, Center for Drug Evaluation and Research (CDER). Bioavailability and bioequivalence studies for orally administered drug products-general considerations. Rockville, MD: U.S. Department of Health and Human Services FaDA, Center for Drug Evaluation and Research (CDER), 2003:1-23.
  11. Obuchowski NA and Zhou XH. Prospective studies of diagnostic test accuracy when disease prevalence is low. Biostatistics 2002;3:477-92. https://doi.org/10.1093/biostatistics/3.4.477